20/20 Biolabs, Inc. (AIDX)

20/20 Biolabs Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Cash & Equivalents	1.14	1.78	4.09
Cash & Cash Equivalents	1.14	1.78	4.09
Cash Growth	-	-56.38%	-
Receivables	0.14	0.14	0.07
Inventory	0.05	0.05	0.06
Other Current Assets	0.23	0.07	0.08
Total Current Assets	1.57	2.03	4.3
Property, Plant & Equipment	-	0.12	0.24
Goodwill and Intangibles	-	1.27	1.46
Other Long-Term Assets	-	0.16	0.36
Total Long-Term Assets	-	1.55	2.07
Total Assets	-	3.58	6.37
Accounts Payable	-	0.37	0.36
Deferred Revenue	-	0.47	0.25
Current Debt	-	0.17	0.16
Other Current Liabilities	1.99	0.35	0.23
Total Current Liabilities	1.99	1.36	1.01
Long-Term Debt	-	0.67	1.07
Other Long-Term Liabilities	-	0.05	0
Total Long-Term Liabilities	-	0.72	1.07
Total Liabilities	-	2.08	2.08
Total Debt	1.16	0.84	1.23
Debt Growth	-	-31.88%	-
Retained Earnings	-	-29.51	-23.96
Shareholders' Equity	0.11	1.51	4.29
Net Cash (Debt)	-0.01	0.94	2.86
Net Cash (Debt) Growth	-	-66.94%	-
Working Capital	-0.43	0.68	3.29

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).